[Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia].
Tao Wu(Anyang Tumor Hospital), Yang Wang(Peking University), J L Zhang(307th Hospital of Chinese People’s Liberation Army), Ying Han(Fujian University of Traditional Chinese Medicine), Harrison X. Bai(Brown University), Dandan Mao(Kunming University of Science and Technology), Rui Xi(Shanghai University of Engineering Science)
Cited by 1
Related Papers
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
|Frontiers in Pharmacology|2019|287
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
|Chinese Journal of Cancer Research|2019|126
Effects of lanthanum, cerium, and neodymium on the nuclei and mitochondria of hepatocytes: Accumulation and oxidative damage
|Environmental Toxicology and Pharmacology|2010|113